Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Kidney Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 30Nivolumab 30cabozantinib 20Ipilimumab 15Magnetic Resonance Spectroscopy 14belzutifan 13lenvatinib 11Axitinib 9Specimen Handling 8Sunitinib 7durvalumab 5CTLA-4 Antigen 5tislelizumab 4atezolizumab 4Radiosurgery 4Interleukin-2 4Everolimus 4Biopsy 4Bevacizumab 4pazopanib 3avelumab 3aldesleukin 3Immunoglobulin G 3Disulfides 3palbociclib 2fludarabine 2entinostat 2adavosertib 2Surveys and Questionnaires 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Renal Cell × guadecitabine × Clear all
NCT03308396 2022-02-17

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Big Ten Cancer Research Consortium

Phase 1/2 Active not recruiting
57 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡